STOK
Stoke Therapeutics, Inc.
Key Financials
Revenue
$184.4M
↑ 404.5%
Net Income
$-6885000
↑ 92.3%
Operating Income
$-20590000
↑ 79.7%
EPS (Diluted)
$-0.12
↑ 92.7%
Total Assets
$418.4M
↑ 54.1%
Total Liabilities
$66.0M
↑ 55.1%
Shareholders' Equity
$352.5M
↑ 53.9%
Cash & Equivalents
$84.2M
↓ 34.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/18/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
| 144 | 5/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | STOK |
| Company Name | Stoke Therapeutics, Inc. |
| CIK | 1623526 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 781-430-8200 |